دورية أكاديمية
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
| العنوان: | Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group. |
|---|---|
| المؤلفون: | Steffanoni S; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy., Calimeri T; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy., Laurenge A; Service de Neurologie 2-Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France., Fox CP; Hematology Department, University Hospitals NHS Trust, Nottingham, UK., Soussain C; Hôpital René Huguenin-Institut Curie, Saint-Cloud, Paris, France., Grommes C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA., Tisi MC; Division of Hematology, Ospedale San Bortolo, Vicenza, Italy., Boot J; Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK., Crosbie N; Derriford Hospital, Plymouth, UK., Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy., Arcaini L; Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy., Chaganti S; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK., Sassone MC; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy., Alencar A; Department of Hematology and Oncology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, USA., Armiento D; Division of Hematology, Campus Bio Medico, Rome, Italy., Romano I; Division of Hematology, Ospedale Careggi, Florence, Italy., Dietrich J; Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA., Itchaki G; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel., Bruna R; Division of Hematology, Ospedale Maggiore, Novara, Italy., Fracchiolla NS; UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy., Arletti L; Division of Hematology, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy., Venditti A; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy., Booth S; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK., Musto P; Department of Emergency and Organ Transplantation, 'Aldo Moro' University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy., Hoang Xuan K; Service de Neurologie 2-Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France., Batchelor TT; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Cwynarski K; Department of Haematology, University College London Hospital, London, UK., Ferreri AJM; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy. |
| المصدر: | British journal of haematology [Br J Haematol] 2022 Nov; Vol. 199 (4), pp. 507-519. Date of Electronic Publication: 2022 Aug 09. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 0372544 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2141 (Electronic) Linking ISSN: 00071048 NLM ISO Abbreviation: Br J Haematol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Oxford : Wiley-Blackwell Original Publication: Oxford : Blackwell Scientific Publications |
| مواضيع طبية MeSH: | COVID-19* , Lymphoma*/drug therapy, Humans ; SARS-CoV-2 ; Central Nervous System |
| مستخلص: | To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six. Among the 64 patients infected before/during first-line chemotherapy, 38 (59%) developed pneumonia and 26 (41%) did not clear the virus. Prolonged exposure to steroids before viral infection and/or treatment with high-dose cytarabine favoured pneumonia development and virus persistence and were associated with poorer survival; 81% of patients who did not clear virus died early from coronavirus disease 2019 (COVID-19). Vaccination was associated with lower pneumonia incidence and in-hospital mortality. Chemotherapy was initiated/resumed in 43 (67%) patients, more commonly among patients who did not develop pneumonia, cleared the virus, or did not receive steroids during infection. Chemotherapy resumption in patients with viral persistence should be indicated cautiously as it was associated with a poorer survival (6-month, 70% and 87%, p = 0.07). None of the 21 patients infected during follow-up died from COVID-19, requiring similar measures as infected subjects in the general population. (© 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.) |
| References: | de Azambuja E, Brandao M, Wildiers H, Laenen A, Aspeslagh S, Fontaine C, et al. Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis. ESMO Open. 2020;5(5):e000947-000947. Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, et al. COVID-19 in breast cancer patients: a cohort at the Institut curie hospitals in the Paris area. Breast Cancer Res. 2020;22(1):55-020-01293-8. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-18. Zarifkar P, Kamath A, Robinson C, Morgulchik N, Shah SFH, Cheng TKM, et al. Clinical characteristics and outcomes in patients with COVID-19 and cancer: a systematic review and meta-analysis. Clin Oncol (R Coll Radiol). 2021;33(3):e180-91. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-45. Pagano L, Salmanton-Garcia J, Marchesi F, Busca A, Corradini P, Hoenigl M, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168-021-01177-0. Perini GF, Fischer T, Gaiolla RD, Rocha TB, Bellesso M, Teixeira LLC, et al. How to manage lymphoid malignancies during novel 2019 coronavirus (CoVid-19) outbreak: a Brazilian task force recommendation. Hematol Transfus Cell Ther. 2020;42(2):103-10. Di Ciaccio P, McCaughan G, Trotman J, Ho PJ, Cheah CY, Gangatharan S, et al. Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID-19 pandemic. Intern Med J. 2020;50(6):667-79. Waghmare A, Abidi MZ, Boeckh M, Chemaly RF, Dadwal S, El Boghdadly Z, et al. Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients. Biol Blood Marrow Transplant. 2020;26(11):1983-94. Willan J, King AJ, Hayes S, Collins GP, Peniket A. Care of haematology patients in a COVID-19 epidemic. Br J Haematol. 2020;189(2):241-3. Weinkove R, McQuilten ZK, Adler J, Agar MR, Blyth E, Cheng AC, et al. Managing haematology and oncology patients during the COVID-19 pandemic: interim consensus guidance. Med J Aust. 2020;212(10):481-9. Rasschaert M, Vanclooster P, Depauw L, Mertens T, Roelant E, Coenen E, et al. Meeting the challenges in cancer care management during the SARS-Cov-2 pandemic: a retrospective analysis. Cancer Control. 2021;28:1-9. Ribera JM, Morgades M, Coll R, Barba P, Lopez-Lorenzo JL, Montesinos P, et al. Frequency, clinical characteristics and outcome of adults with acute lymphoblastic leukemia and COVID 19 infection in the first vs. Second Pandemic Wave in Spain. Clin Lymphoma Myeloma Leuk. 2021;21(10):e801-9. Sanchez-Velazquez A, Bauer-Alonso A, Estrach T, Vega-Diez D, Garcia-Muret P, Haya L, et al. Patients with primary cutaneous lymphoma are at risk for severe COVID-19. Data from the Spanish primary cutaneous lymphoma registry. J Eur Acad Dermatol Venereol. 2021;35(10):e624-6. Chatzikonstantinou T, Kapetanakis A, Scarfo L, Karakatsoulis G, Allsup D, Cabrero AA, et al. COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and campus CLL study. Leukemia. 2021;35(12):3444-54. Laurenge A, Ursu R, Houillier C, Abdi B, Tebano G, Quemeneur C, et al. SARS-CoV-2 infection in patients with primary central nervous system lymphoma. J Neurol. 2021;268(9):3072-80. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;25:1-8. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180(8):1081-9. Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23(22):5034-43. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18(17):3144-50. Fritsch K, Kasenda B, Schorb E, Hau P, Bloehdorn J, Mohle R, et al. High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study). Leukemia. 2017;31(4):846-52. Ferreri AJ, Cwynarski K, Pulczynski E, Ponzoni M, Deckert M, Politi LS, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the international Extranodal lymphoma study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3(5):e217-27. Herishanu Y, Rahav G, Levi S, Braester A, Itchaki G, Bairey O, et al. Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard two-dose vaccination. Blood. 2022;139(5):678-85. Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021;5(16):3053-61. Schmidt AL, Labaki C, Hsu CY, Bakouny Z, Balanchivadze N, Berg SA, et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann Oncol. 2022;33(3):340-6. Regalado-Artamendi I, Jimenez-Ubieto A, Hernandez-Rivas JA, Navarro B, Nunez L, Alaez C, et al. Risk factors and mortality of COVID-19 in patients with lymphoma: a multicenter study. Hema. 2021;5(3):e538. Robilotti EV, Babady NE, Mead PA, Rolling T, Perez-Johnston R, Bernardes M, et al. Determinants of COVID-19 disease severity in patients with cancer. Nat Med. 2020;26(8):1218-23. Lamure S, Dulery R, Di Blasi R, Chauchet A, Laureana C, Deau-Fischer B, et al. Determinants of outcome in Covid-19 hospitalized patients with lymphoma: a retrospective multicentric cohort study. EClinicalMedicine. 2020;27:100549. Mato AR, Roeker LE, Lamanna N, Allan JN, Leslie L, Pagel JM, et al. Outcomes of COVID-19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43. Sah P, Fitzpatrick MC, Zimmer CF, Abdollahi E, Juden-Kelly L, Moghadas SM, et al. Asymptomatic SARS-CoV-2 infection: a systematic review and meta-analysis. Proc Natl Acad Sci U S A. 2021;118(34):1-12. Gianfrancesco M, Hyrich KL, Al-Adely S, Carmona L, Danila MI, Gossec L, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859-66. Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5(12):2624-43. Gottlieb RL, Vaca CE, Paredes R, Mera J, Webb BJ, Perez G, et al. Early Remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med. 2022;386(4):305-15. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for Oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509-20. Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016;57(3):512-9. Visco C, Marcheselli L, Mina R, Sassone M, Guidetti A, Penna D, et al. A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study. Blood Adv. 2022;6(1):327-38. |
| معلومات مُعتمدة: | P30 CA008748 United States CA NCI NIH HHS |
| فهرسة مساهمة: | Keywords: coronavirus disease 2019 (COVID-19); pneumonia; primary central nervous system lymphoma; severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); steroid therapy; vaccine |
| تواريخ الأحداث: | Date Created: 20220809 Date Completed: 20221110 Latest Revision: 20230118 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC9538907 |
| DOI: | 10.1111/bjh.18396 |
| PMID: | 35945164 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1365-2141 |
|---|---|
| DOI: | 10.1111/bjh.18396 |